127 related articles for article (PubMed ID: 19663703)
1. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3.
Gorbenko O; Ovcharenko G; Klymenko T; Zhyvoloup O; Gaman N; Volkova D; Gout I; Filonenko V
Hybridoma (Larchmt); 2009 Aug; 28(4):295-300. PubMed ID: 19663703
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies with selective specificity towards different glycosylation isoforms of FGFR1.
Gorbenko O; Ovcharenko G; Volkova D; Mayilo D; Gaman N; Khozhayenko Y; Usenko V; Gout I; Filonenko V
Hybridoma (Larchmt); 2009 Aug; 28(4):287-93. PubMed ID: 19663702
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4).
Chen C; Patel S; Corisdeo S; Liu X; Micolochick H; Xue J; Yang Q; Lei Y; Wang B; Soltis D
Hybridoma (Larchmt); 2005 Jun; 24(3):152-9. PubMed ID: 15943563
[TBL] [Abstract][Full Text] [Related]
4. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
5. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
7. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
8. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
Tomlinson DC; Hurst CD; Knowles MA
Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
[TBL] [Abstract][Full Text] [Related]
9. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
10. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of monoclonal antibodies to mTOR kinase.
Nemazanyy I; Breus O; Gout I; Filonenko V; Panasyuk G
Hybridoma (Larchmt); 2008 Oct; 27(5):395-9. PubMed ID: 18803507
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of monoclonal antibodies against tuberous sclerosis complex 2.
Malanchuk O; Palchevskyy S; Ovcharenko G; Gwalter J; Pozur V; Gout I; Filonenko V
Hybridoma (Larchmt); 2007 Aug; 26(4):259-66. PubMed ID: 17725389
[TBL] [Abstract][Full Text] [Related]
14. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
Bernard-Pierrot I; Brams A; Dunois-Lardé C; Caillault A; Diez de Medina SG; Cappellen D; Graff G; Thiery JP; Chopin D; Ricol D; Radvanyi F
Carcinogenesis; 2006 Apr; 27(4):740-7. PubMed ID: 16338952
[TBL] [Abstract][Full Text] [Related]
16. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
[TBL] [Abstract][Full Text] [Related]
17. FGFR
Xie X; Lin J; Zhong Y; Fu M; Tang A
Exp Ther Med; 2019 Aug; 18(2):1226-1234. PubMed ID: 31316618
[TBL] [Abstract][Full Text] [Related]
18. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.
Zhou H; He F; Mendelsohn CL; Tang MS; Huang C; Wu XR
Sci Rep; 2016 May; 6():25596. PubMed ID: 27157475
[TBL] [Abstract][Full Text] [Related]
19. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
20. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]